Show notes
Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech.
Transcript
Transcript not available for this episode yet.
More from The Top Line
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Aug 7, 202620 min
The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Aug 6, 202626 min
Inside Noble’s connected approach to patient support (Sponsored)
Aug 3, 202615 min
Psychedelics, peptides and GLP-1s
Jul 31, 202625 min
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min